FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800664098> ?p ?o ?g. }

• W2800664098 endingPage "e6" @default.
• W2800664098 startingPage "e6" @default.
• W2800664098 abstract "Tumor treating fields (TTF) are a low-intensity, intermediate-frequency, non-invasive and regional anti-mitotic treatment that harnesses magnetic fields to induce apoptosis in targeted regions. A Food and Drug Administration-approved TTF system demonstrated a significant increase in survival of newly diagnosed glioblastoma multiforme (GBM) in 2014. One year later, in a landmark randomized phase III trial of newly diagnosed GBM patients, TTF + temozolomide demonstrated superiority to temozolomide alone. Given these findings, we sought to assess practice patterns and trends of providers in the utilization of TTF for GBM. A survey designed through the Oregon Clinical and Translational Research Institute was administered to practices in the United States which self-identified as specializing in radiation oncology, medical oncology, neuro-oncology, neurosurgery, and/or neurology. Responses were collected anonymously; the survey was constructed to assess responder knowledge of appropriate clinical scenarios for TTF, knowledge of TTF therapy status on National Comprehensive Cancer Network (NCCN) guidelines, and personal approaches for patients with recurrent GBM, as well as additional demographic data. A total of 106 providers responded; 95% were practicing physicians representing Missouri (8.9%), Massachusetts (7.9%), California (6.9%), Philadelphia (5.9%), Oregon (5.9%), and Illinois (5.9%). The most common responders were radiation oncologists (75%) and neuro-oncologists (22%); medical oncologists (3%) and neurosurgeons (1%) comprised the remaining responders. The average number of physician-partners in a responder’s practice group was 7.6; a minority (36%) were in private practice. With regard to case volume, only 18% treated 0-5 high-grade gliomas per year, while 24% treated 6-10 annually, and 58% treated at least 10 high-grade gliomas annually. The provider most commonly reported as certified to offer TTF therapy to GBM patients was the neuro-oncologist (40%), followed by the radiation oncologist (34%); 31% reported no physician in their practice being certified to offer TTF therapy. The vast majority of TTF for GBM in the United States is administered by neuro-oncologists and radiation oncologists, usually in an academic setting involving 7-8 physician-partners. More than 80% of TTF is performed by groups who treat at least six high-grade gliomas per year. However, one-fifth of providers were unaware of TTF therapy being listed on current NCCN guidelines for GBM treatment, and more than 30% were in practices bereft of anyone certified to offer TTF therapy. These results indicate that there remains fertile soil for TTF therapy nationwide to be introduced into practices for GBM treatment. Given the promising results of TTF for GBM in clinical trials thus far, this opportunity should be seized energetically." @default.
• W2800664098 created "2018-05-17" @default.
• W2800664098 creator A5013321795 @default.
• W2800664098 creator A5037724529 @default.
• W2800664098 creator A5059739662 @default.
• W2800664098 creator A5070140716 @default.
• W2800664098 creator A5073476934 @default.
• W2800664098 creator A5087295298 @default.
• W2800664098 date "2018-06-01" @default.
• W2800664098 modified "2023-09-25" @default.
• W2800664098 title "(OA14) Application of Tumor Treating Fields for Newly Diagnosed Glioblastoma Multiforme: Understanding of Nationwide Practice Patterns and Trends" @default.
• W2800664098 doi "https://doi.org/10.1016/j.ijrobp.2018.02.053" @default.
• W2800664098 hasPublicationYear "2018" @default.
• W2800664098 type Work @default.
• W2800664098 sameAs 2800664098 @default.
• W2800664098 citedByCount "0" @default.
• W2800664098 crossrefType "journal-article" @default.
• W2800664098 hasAuthorship W2800664098A5013321795 @default.
• W2800664098 hasAuthorship W2800664098A5037724529 @default.
• W2800664098 hasAuthorship W2800664098A5059739662 @default.
• W2800664098 hasAuthorship W2800664098A5070140716 @default.
• W2800664098 hasAuthorship W2800664098A5073476934 @default.
• W2800664098 hasAuthorship W2800664098A5087295298 @default.
• W2800664098 hasBestOaLocation W28006640981 @default.
• W2800664098 hasConcept C121608353 @default.
• W2800664098 hasConcept C126322002 @default.
• W2800664098 hasConcept C12770488 @default.
• W2800664098 hasConcept C141071460 @default.
• W2800664098 hasConcept C142724271 @default.
• W2800664098 hasConcept C143998085 @default.
• W2800664098 hasConcept C2776194525 @default.
• W2800664098 hasConcept C2777389519 @default.
• W2800664098 hasConcept C2779130545 @default.
• W2800664098 hasConcept C2779974597 @default.
• W2800664098 hasConcept C2992520072 @default.
• W2800664098 hasConcept C502942594 @default.
• W2800664098 hasConcept C509974204 @default.
• W2800664098 hasConcept C512399662 @default.
• W2800664098 hasConcept C535046627 @default.
• W2800664098 hasConcept C71924100 @default.
• W2800664098 hasConceptScore W2800664098C121608353 @default.
• W2800664098 hasConceptScore W2800664098C126322002 @default.
• W2800664098 hasConceptScore W2800664098C12770488 @default.
• W2800664098 hasConceptScore W2800664098C141071460 @default.
• W2800664098 hasConceptScore W2800664098C142724271 @default.
• W2800664098 hasConceptScore W2800664098C143998085 @default.
• W2800664098 hasConceptScore W2800664098C2776194525 @default.
• W2800664098 hasConceptScore W2800664098C2777389519 @default.
• W2800664098 hasConceptScore W2800664098C2779130545 @default.
• W2800664098 hasConceptScore W2800664098C2779974597 @default.
• W2800664098 hasConceptScore W2800664098C2992520072 @default.
• W2800664098 hasConceptScore W2800664098C502942594 @default.
• W2800664098 hasConceptScore W2800664098C509974204 @default.
• W2800664098 hasConceptScore W2800664098C512399662 @default.
• W2800664098 hasConceptScore W2800664098C535046627 @default.
• W2800664098 hasConceptScore W2800664098C71924100 @default.
• W2800664098 hasIssue "2" @default.
• W2800664098 hasLocation W28006640981 @default.
• W2800664098 hasOpenAccess W2800664098 @default.
• W2800664098 hasPrimaryLocation W28006640981 @default.
• W2800664098 hasRelatedWork W1521636633 @default.
• W2800664098 hasRelatedWork W2065523055 @default.
• W2800664098 hasRelatedWork W2120698060 @default.
• W2800664098 hasRelatedWork W2313927983 @default.
• W2800664098 hasRelatedWork W2770595181 @default.
• W2800664098 hasRelatedWork W2948021937 @default.
• W2800664098 hasRelatedWork W3100182543 @default.
• W2800664098 hasRelatedWork W3173223947 @default.
• W2800664098 hasRelatedWork W4282971088 @default.
• W2800664098 hasRelatedWork W4295758394 @default.
• W2800664098 hasVolume "101" @default.
• W2800664098 isParatext "false" @default.
• W2800664098 isRetracted "false" @default.
• W2800664098 magId "2800664098" @default.
• W2800664098 workType "article" @default.